Fusion Proteins with Unstructured Polypeptides for Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein therapeutic delivery methods face challenges such as rapid clearance, limited specificity, and aggregation issues, making it difficult to effectively translate protein-based therapies to the clinic.
Innovation Solution
Development of fusion proteins comprising binding polypeptides and unstructured polypeptides, such as elastin-like polypeptides, with linkers like Gly4Ser, which form depot-like structures for controlled release, allowing for targeted binding to cell surface receptors like TRAILR-2 and potentially treating diseases like colorectal adenocarcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein therapeutics are administered to treat diseases, then therapeutic efficacy is achieved, but rapid clearance and aggregation issues occur
Solution Approach 1:
The patent merges binding polypeptides (responsible for therapeutic activity) with unstructured polypeptides (forming gel-like depots) into fusion proteins. This combination allows the therapeutic protein to be delivered in a sustained-release format, reducing rapid clearance while maintaining efficacy. The unstructured polypeptide component forms a depot that slowly releases the binding polypeptide over time, extending the duration of action.
Solution Approach 2:
The fusion protein creates a composite structure where structured binding domains are fused with unstructured polypeptide regions. This composite architecture allows the protein to exhibit both binding specificity and depot-forming capabilities, solving the contradiction between rapid clearance and sustained therapeutic action.
2Measurement precision
If protein therapeutics are engineered for high affinity and specificity, then target binding is improved, but delivery and clearance become more problematic
Solution Approach 1:
The protein is segmented into distinct functional domains: binding polypeptides that provide high-affinity target binding and unstructured polypeptides that provide delivery advantages. This segmentation allows each component to be optimized independently - the binding domains for specificity and the unstructured regions for depot formation and controlled release.
Solution Approach 2:
The unstructured polypeptide acts as an intermediary between the binding polypeptide and the extracellular environment. It forms a gel-like depot that controls the release of the binding polypeptide, mediating the delivery process and reducing rapid clearance while maintaining binding specificity.
3Reliability
If multivalent binding polypeptides are used to increase potency, then target engagement is improved, but protein complexity and aggregation increase
Solution Approach 1:
Multiple binding polypeptides are merged with unstructured polypeptides in a fusion protein architecture. This combination allows the multivalent binding units to be delivered in a controlled manner through the unstructured polypeptide depot, reducing aggregation issues while maintaining the enhanced potency provided by multiple binding sites.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion proteins demonstrate potent therapeutic efficacy by forming gel-like depots that provide sustained release, maintaining potency and specificity, leading to partial tumor regression and delayed tumor growth in mouse models.
Implementation Method 1
The unstructured polypeptide comprises an elastin-like polypeptide... the fusion protein forms gel-like depots that provide sustained release
Data Source
AI summary
Provided herein are fusion proteins including at least one binding polypeptide and at least one unstructured polypeptide. The fusion protein may further include at least one linker. Further provided are methods for determining the presence of a target in a sample, methods of treating a disease, methods of diagnosing a disease in a subject, and methods of determining the effectiveness of a treatment for a disease in a subject. The methods may include administering to the subject an effective amount of the fusion protein.